Biogen has agreed to acquire Apellis Pharmaceuticals after an extended negotiation process. The company also entered a collaboration with Alloy Therapeutics focused on antisense drug development using ...
Biogen Inc. (Nasdaq: BIIB) and TJ Biopharma ("TJ Bio") today announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio's exclusive rights to ...
Biogen (BIIB) has reached a deal worth up to $850M with TJ Bio to acquire exclusive rights in Greater China for felzartamab, an antibody therapy designed to target various immune-mediated disorders, ...
When a biopharma company known for its expertise in a specific domain turns to a collaborator to expand its capabilities in ...
Biogen Inc. (NASDAQ: BIIB) stock climbed Monday as the company and TJ Biopharma announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio’s ...
Vietnam Investment Review on MSN
TJ Biopharma acquires Biogen s Greater China felzartamab rights
CAMBRIDGE, Mass. and HANGZHOU, China, April 20, 2026 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and TJ Biopharma ("TJ Bio") today announced that the companies have entered into a definitive agreement ...
Biogen recorded declining sales for Spinraza in each of the four quarters of 2025, but the Massachusetts drugmaker sees positive signs with the recent launch of its high-dose (HD) version of the ...
(RTTNews) - Biogen Inc. (BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company, announced Tuesday a strategic collaboration to develop select novel RNAi therapies. Through the ...
Biogen (NASDAQ:BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ((RNAi)) therapies targeting serious diseases. Under the agreement, City Therapeutics will use its ...
UCB SA (OTC:UCBJY) (OTC:UCBJF) (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) on Thursday presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab ...
With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results